Teva's legal set-aside hits $1 billion as opioid deal hits snags by Kyle Blankenship Thursday, November 7, 2019 With an eye-popping $23 billion deal on the table to settle its opioid suits, Teva is setting aside even more funds to cover its possible liabilities.
Sun Pharma chief, Dr. Reddy's, Natco and more—FiercePharmaAsia by Angus Liu Friday, August 16, 2019 Sun's Shanghvi took a 99% pay cut last year. Dr. Reddy's copies of Copaxone and NuvaRing were rejected by the FDA. Natco eyes China amid hardship.
Teva shares approach 20-year low amid Moody's warning by Arlene Weintraub Thursday, August 15, 2019 Debt-rating firm Moody's revised its Teva outlook from "stable" to "negative" as the company deals with multiple challenges.
Dr. Reddy's Copaxone, NuvaRing generics derailed by FDA by Eric Palmer Wednesday, August 14, 2019 Dr. Reddy’s, which has been dealing with manufacturing setbacks, has received a complete response letter for two potentially lucrative products.
China rolls out copycat target list to boost generic development by Angus Liu Thursday, June 20, 2019 With the list of 34 drugs, the Chinese government is encouraging drugmakers to copy them under regulator's priority review pathway.
Teva closes in on $3B cost-cutting goal by Eric Sagonowsky Thursday, May 2, 2019 So far in Teva's extensive cost-cutting drive, 10,000 people have left the company, CEO Kåre Schultz said Thursday.
Where's Mylan planning to put its ramped-up 2019 spending? by Carly Helfand Wednesday, February 27, 2019 Mylan is in the midst of rolling out several key drugs, so extra spend might be warranted. But analysts worry whether that outlay will pay off.
Teva forecasts tough year as generics hammer Copaxone by Arlene Weintraub Wednesday, February 13, 2019 Teva's Copaxone is losing ground to generic competition—and the company's newer drugs aren’t taking off fast enough to make up for the loss.
Mylan's generic Advair discount not as big as it looks: analysts by Carly Helfand Wednesday, February 13, 2019 Mylan has set its list price for its Advair copy at a 70% discount to the brand. But the move may not be as dramatic as it seems.
Rebounding Teva is ‘too cheap to ignore,' upbeat analysts say by Angus Liu Friday, February 8, 2019 What kind of difference can one year make? Just ask some Teva analysts, who are upbeat that the drugmaker's cost-cutting measures are paying off.
